menu
    • menu
    [{"orgOrder":0,"company":"Matthew James","sponsor":"Alberta Health services | University of Alberta","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Cilastatin Sodium","moa":"Renal dipeptidase","graph1":"Nephrology","graph2":"Phase II","graph3":"Matthew James","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Matthew James \/ Alberta Health services | University of Alberta","highestDevelopmentStatusID":"8","companyTruncated":"Matthew James \/ Alberta Health services | University of Alberta"}]

    Find Clinical Drug Pipeline Developments & Deals for IMIPENEM; CILASTATIN

    Menu

    IMIPENEM; CILASTATIN

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Matthew James

                            Country arrow
                            FNCE
                            Not Confirmed

                            Matthew James

                            Country arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cilastatin Sodium

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Alberta Health services | University of Alberta

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Prevention of Nephrotoxin-Induced Acute Kidney Injury Using Cilastatin

                            Details : Cilastatin Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Acute Kidney Injury.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 20, 2025

                            Lead Product(s) : Cilastatin Sodium

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Alberta Health services | University of Alberta

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth